The central OT system acts as but one component of a complex neurochemical milieu in which gonadal steroids also play a significant part. As extensively discussed in recent full-length reviews, gonadal steroid hormones (i.e., estrogen, progesterone, and testosterone), and the two nonapeptides – OT and arginine vasopressin (AVP) – coevolved, all playing a vital role in mammalian social development through their unique influence on parental bonding, mate choice, and attachment (van Anders et al.,
2011; Bos et al.,
2012). In toto, there is substantial evidence indicating that at least some of oxytocin’s effects are correlated with an individual’s sex, in part via the influence of gonadal hormones. We can only give this important topic brief review, and direct the reader to more comprehensive treatments (van Anders et al.,
2011; Bos et al.,
2012; Gabor et al.,
2012).
As background, animal studies indicate that sex-specific differences in response to OT are common (Williams et al.,
1994; Cho et al.,
1999; Bales and Carter,
2003; Bales et al.,
2007), and the histological structure for OT neurons is sexually dimorphic, suggesting that sex steroids play a role in early morphogenesis of this system (de Vries,
2008). Estrogen upregulates OT and OT receptor (OTR) production (Patisaul et al.,
2003; Windle et al.,
2006; Choleris et al.,
2008), whereas testosterone promotes both OTR binding in the hypothalamus (Johnson et al.,
1991) as well as production of AVP (Delville et al.,
1996), which has many opponent actions to OT (Neumann and Landgraf,
2012). In humans, moreover, testosterone seems from one perspective to have opposite behavioral effects to the prosocial impact classically associated with OT: decreasing trust, generosity, empathy (van Honk and Schutter,
2007; Zak et al.,
2009; Bos et al.,
2010), though more recent conceptualizations of the parochial, “us vs. them” aspect of OT make this picture more complex, and evidence OT’s “darker” side (Shamay-Tsoory et al.,
2009; De Dreu et al.,
2010,
2011,
2012; Declerck et al.,
2010). Though OT is only one small piece of the complex psychobiology of gender, some have posited different OT-biased relational strategies for the sexes, with females more prone to “tend and befriend” (Taylor et al.,
2000; but, see Smith et al.,
2012b), whereas more warrior-prone, hierarchy-bound males “compete and defeat” (David and Lyons-Ruth,
2005; Smeets et al.,
2009; Van Vugt,
2009; Gabor et al.,
2012).
More evidence for sex-specific differences in the OT system come from research indicating that men and women show differences in plasma OT levels (Ozsoy et al.,
2009; Gordon et al.,
2010; Holt-Lunstad et al.,
2011; Weisman et al.,
2012b), as well as gender-specific behavioral correlations with OT (Gordon et al.,
2010; Zhong et al.,
2012; but, see Szeto et al.,
2011 for critique of plasma OT measurement techniques). Coming from the perspective of genetic variations in nonapeptide receptors, Walum et al. (
2012) have found an association between the OTR variant rs7632287 and pair-bonding behaviors in women but not in men, whereas an earlier study found an association of an AVP receptor polymorphism and pair-bonding in
men but not women (Walum et al.,
2008). Furthermore, numerous studies in the growing OTR literature note sex-specific associations between genetic variants in the OTR gene and personality characteristics (Stankova et al.,
2012), neural responses to emotionally salient cues (Tost et al.,
2010), hypothalamic gray matter volume (Tost et al.,
2010), and empathy (Wu et al.,
2012), though other studies in this area have failed to find a sex bias (Rodrigues et al.,
2009; Saphire-Bernstein et al.,
2011; Feldman et al.,
2012). A final set of salient investigations found that amygdala-prefrontal cortical connectivity – which can be impacted by OT in normal subjects (Sripada et al.,
2012) and anxiety patients (Labuschagne et al.,
2011) – may be related in a gender-specific way to the development of anxiety and depressive disorders (Burghy et al.,
2012), both putative clinical targets for intranasal oxytocin (IN OT) (Slattery and Neumann,
2010; Neumann and Landgraf,
2012).
Focusing on clinical OT trials using IN OT, gender-dependent effects have been demonstrated in some single-dose studies (Hurlemann et al.,
2010), including studies of effects on they amygdala (Domes et al.,
2010; Rupp et al.,
2012), and interpersonal behavior (Liu et al.,
2012) but – consistent with the variability in this literature – many other single-dose studies have not found an effect of sex (see Bartz et al.,
2011b for review). A recently investigated individual factor at least partly related to sex (due to different sexual selection strategies between males and females; Ihara and Aoki,
1999) is the relationship status of the person receiving the drug. Specifically, Scheele et al. (
2012) found in a group of 86 normal heterosexual males that IN OT preferentially stimulated men in a monogamous relationship – but not single males – to maintain more personal space from women (but not men). Whether these effect would cross over to females and same-sex relationships in interesting and unexplored.
Though the suggestion of gender effects in single-dose studies of normal subjects may be informative, as discussed in the accompanying larger review (MacDonald and Feifel), these results do not speak directly to the clinical question of whether sex differences moderate the effects of chronic OT treatment in clinically ill populations. The first study to intimate such a sex moderation effect was a randomized, double-blind, within-subjects crossover study of OT (40 IU BID for 3

weeks) in patients with generalized anxiety disorder (GAD) (Feifel et al.,
2011). This trial demonstrated a trend level dose-by-gender effect such that males treated with OT showed a significant clinical improvement in HAM-A scores with OT, whereas females showed higher HAM-A scores during 3

weeks of treatment. The three extant studies using multiple weeks of OT treatment in patients with schizophrenia demonstrated a male bias in recruitment (62 males treated vs. 13 females), though none showed a sex-by-drug effect (Feifel et al.,
2010; Pedersen et al.,
2011; Modabbernia et al.,
2012). Notable in this context are studies by Rubin et al. (
2010,
2011) indicating that female but not male patients with schizophrenia show a correlation between plasma OT concentrations, perception of facial emotion expression, and psychopathology, as well as evidence that women with borderline personality disorder have reduced plasma OT levels, even after controlling for hormonal factors (Bertsch et al.,
2012).
In terms of future clinical studies with IN OT, the abovementioned sex-specific variables may have at least two repercussions. First, they highlight the importance of monitoring/measuring hormone levels, menstrual phase, and oral contraceptive status in trials with IN OT, given these parameters may impact OT levels (Salonia et al.,
2005, but, see Rubin et al.,
2011) and psychiatric symptoms (Rubin et al.,
2010). Secondly, given that there are sex differences in the incidence of many of the disease states for which OT is a putative treatment (i.e., autism, postpartum depression), further delineation of the role of sex in the effects of chronic OT treatment will be critical.